News

10 October, 2018

Zelluna Immunotherapy appoints Geir Christian Melen as Chief Financial Officer

Appointment to strengthen Zelluna’s financial and operational capabilities

Oslo, Norway, October 24, 2018 - Zelluna Immunotherapy, the biotechnology company specializing in T-cell receptor (TCR) immunotherapies targeting a broad range of solid cancers with a high unmet medical need, announces the appointment of Geir Christian Melen as chief financial officer (CFO).

08 August, 2018

Zelluna Immunotherapy appoints Dr. Namir Hassan as Chief Scientific Officer

Senior management appointment to further strengthen Zelluna research capabilities and portfolio

Oslo, Norway, August 13th, 2018 - Zelluna Immunotherapy, the biotechnology company specializing in T-cell receptor (TCR) immunotherapies targeting a broad range of solid cancers with a high unmet medical need, today announces the appointment of Dr. Namir Hassan as chief scientific officer (CSO).

04 April, 2018

Zelluna Immunotherapy appoints Arjan Roozen as Chief Technology Officer

Appointment to consolidate Zelluna manufacturing strategy towards clinical-phase development

Oslo, Norway, April 16, 2018 - Zelluna Immunotherapy, the biotechnology company specializing in T-cell receptor (TCR) immunotherapies targeting a broad range of solid cancers with a high unmet medical need, today announces the appointment of Arjan Roozen as chief technology officer (CTO).

03 March, 2018

Zelluna Immunotherapy appoints MaSTherCell for process development and manufacturing of TCR adoptive cell therapy platform

Oslo, Norway and Gosselies, Belgium, March 8, 2018 - Zelluna Immunotherapy, a biotechnology company specializing in T-cell receptor (TCR) based immunotherapies for solid tumors with a high unmet medical need, today announces the appointment of MaSTherCell as its contract development and manufacturing (CDMO) partner for the Zelluna TCR adoptive cell therapy platform.

11 November, 2017

Zelluna Immunotherapy appoints Miguel Forte as Chief Executive Officer

Appointment to drive Zelluna through next stage of international clinical-phase development

Oslo, Norway, November 2, 2017 - Zelluna Immunotherapy, the biotechnology company specializing in T-cell receptor (TCR) immunotherapies targeting a broad range of solid cancers with a high unmet medical need, today announces the appointment of Miguel Forte as chief executive officer (CEO).

02 February, 2017

Zelluna Immunotherapy awarded NOK 14 million (USD 1.7 million) from the NRC

The Norwegian Research Council (NRC) has awarded Zelluna Immunotherapy NOK 14 million over a period of 3.5 years through the BIA program for the development of T cell based cancer therapy.

This project supports the overall strategy of the company in bringing new and innovative treatment options for cancer patients.